Regulatory effect of Jiedu Huayu granules on liver injury in mice with acute liver failure and its mechanism

Chengyu YA; Tingshuai WANG; Huiping YAN; Yi WANG; Qingrui ZHAO; Shenglan ZENG; Weiyu CHEN; Rongzhen ZHANG

doi:10.12449/JCH260117

Volume 42 Issue 1

Jan. 2026

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2026 > 42(1): 143-150

PDF( 9590 KB)

Regulatory effect of Jiedu Huayu granules on liver injury in mice with acute liver failure and its mechanism

DOI: 10.12449/JCH260117

Chengyu YA^{1, 2, 3},
Tingshuai WANG^{1, 3, 4},
Huiping YAN¹,
Yi WANG¹,
Qingrui ZHAO^{1, 3, 4},
Shenglan ZENG^{1, 3, 4},
Weiyu CHEN¹,
Rongzhen ZHANG^{2
,
,
,}

1.
Graduate School of Guangxi University of Chinese Medicine，Nanning 530200，China
2.
Department of Hepatobiliary Medicine，International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine，Nanning 530201，China
3.
Key Laboratory of Clinical Research on Traditional Chinese Medicine，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China
4.
Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

National Natural Science Foundation of China (82160881);

National Natural Science Foundation of China (82460901);

Guangxi University Young and Middle-aged Teachers’ Basic Research Ability Improvement Project (2023KY0307);

Guangxi Natural Science Foundation (2021GXNSFAA220112);

Guangxi Natural Science Foundation (2024GXNSFDA999066);

The Third Batch of “Qihuang Project” High-Level Talent Team Cultivation Program of Guangxi University of Chinese Medicine (202409)

More Information

Corresponding author: ZHANG Rongzhen， zhangrongzhen2007@163.com （ORCID： 0000-0003-2243-665X）
Received Date: 2025-07-23
Accepted Date: 2025-09-24
Published Date: 2026-01-25

Abstract

Abstract

Objective To investigate the mechanism of action of Jiedu Huayu granules in improving liver injury in mice with acute liver failure （ALF） by observing its effect on a mouse model of ALF after prophylactic administration， and to provide a basis for clinical medication. Methods A total of 60 specific pathogen-free male C57BL/6J mice were divided into normal group， model group， Jiedu Huayu granules group （JDHY group）， and farnesoid X receptor （FXR） agonist （GW4064） group using a random number table， with 15 mice in each group. The model of ALF was induced by a single intraperitoneal injection of D-galactosamine combined with lipopolysaccharide. The mice in the JDHY group were given prophylactic administration of 0.3 g/mL drug solution of Jiedu Huayu granules by gavage for 3 days before modeling， those in the normal group and the model group were given 0.9% NaCl solution by gavage， and those in the GW4064 group were given intraperitoneal injection of GW4064 for 3 consecutive days before modeling. The mice were sacrificed after modeling， and serum and liver tissue samples were collected. A veterinary automatic biochemical analyzer was used to measure the serum levels of total bilirubin （TBil）， total bile acids （TBA）， gamma-glutamyl transferase （GGT）， alanine aminotransferase （ALT）， and aspartate aminotransferase （AST） in mice from each group； HE staining was used to observe liver pathological changes； RT-PCR was used to measure the mRNA expression levels of FXR， fibroblast growth factor 15 （FGF15）， fibroblast growth factor receptor 4 （FGFR4）， small heterodimer partner （SHP）， and bile salt export pump （BSEP） in mice， and Western blot was used to measure the protein expression levels of FXR， FGF15， FGFR4， SHP， and BSEP. A one-way analysis of variance was used for comparison between groups， and the Dunett method was used for further comparison between two groups. Results Compared with the normal group， the model group had significant increases in the serum levels of TBil， ALT， AST， TBA， and GGT （all P<0.01）， and compared with the model group， the JDHY group and the GW4064 group had significant reductions in the serum levels of TBil， ALT， AST， TBA， and GGT （all P <0.01）. HE staining showed that compared with the model group， the JDHY group and the GW4064 group had milder pathological injury， a reduction in the area of hepatocyte necrosis， and alleviation of cellular swelling and edema. Compared with the normal group， the model group had significant reductions in the mRNA and protein expression levels of FXR， FGF15， FGFR4， SHP， and BSEP in liver tissue （all P <0.01）， and compared with the model group， the JDHY group and the GW4064 group had significant increases in the mRNA and protein expression levels of FXR， FGF15， FGFR4， SHP， and BSEP in liver tissue （all P <0.05）. Conclusion Jiedu Huayu granules may alleviate liver injury in mice with ALF through the FXR/SHP axis.
- Jiedu Huayu Granules,
- Liver Failure，Acute,
- Bile Acid Metabolism

FullText(HTML)

References(30)

References

[1]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
[2]	HARTMANN P, HOCHRATH K, HORVATH A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice[J]. Hepatology, 2018, 67( 6): 2150- 2166. DOI: 10.1002/hep.29676.
[3]	ZHONG YD, CHEN YJ, PAN ZS, et al. Ginsenoside Rc, as an FXR activator, alleviates acetaminophen-induced hepatotoxicity via relieving inflammation and oxidative stress[J]. Front Pharmacol, 2022, 13: 1027731. DOI: 10.3389/fphar.2022.1027731.
[4]	CHEN YY, LAN YM, WANG MG, et al. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. J Clin Hepatol, 2021, 37( 2): 480- 484. DOI: 10.3969/j.issn.1001-5256.2021.02.049. 陈研焰, 蓝艳梅, 王明刚, 等. 胆汁酸-法尼醇核受体R-肠道微生态轴在肝衰竭发生及肝再生中的作用机制[J]. 临床肝胆病杂志, 2021, 37( 2): 480- 484. DOI: 10.3969/j.issn.1001-5256.2021.02.049.
[5]	LYU C, SHI QL, QIN Q, et al. Progress of mechanism of Jiedu Huayu Granules treating hepatic failure[J]. Liaoning J Tradit Chin Med, 2019, 46( 11): 2453- 2457. DOI: 10.13192/j.issn.1000-1719.2019.11.060. 吕超, 石清兰, 覃倩, 等. 解毒化瘀颗粒治疗肝衰竭作用机制研究进展[J]. 辽宁中医杂志, 2019, 46( 11): 2453- 2457. DOI: 10.13192/j.issn.1000-1719.2019.11.060.
[6]	BAI WJ, MAO DW, SHI QL, et al. Effect of Jiedu Huayu Granules on inflammatory state of patients with chronic hepatic failure with toxic heat and stasis syndrome[J]. Chin J Exp Tradit Med Formulae, 2022, 28( 3): 109- 115. DOI: 10.13422/j.cnki.syfjx.20220304. 柏文婕, 毛德文, 石清兰, 等. 解毒化瘀颗粒对慢性肝衰竭毒热瘀结证患者炎症状态的影响[J]. 中国实验方剂学杂志, 2022, 28( 3): 109- 115. DOI: 10.13422/j.cnki.syfjx.20220304.
[7]	SHI QL, MAO DW, CHEN YQ, et al. Effect of Jiedu Huayu Ⅱ Decoction on the expression of Th17 and Th1 in peripheral blood of patients with HBV related acute liver failure and its clinical efficacy[J]. China Med Her, 2018, 15( 21): 122- 125. 石清兰, 毛德文, 陈月桥, 等. 解毒化瘀Ⅱ方对HBV相关急性肝衰竭患者外周血Th17、Th1表达及临床疗效的影响[J]. 中国医药导报, 2018, 15( 21): 122- 125.
[8]	WANG TS, ZHANG RZ, WANG MG, et al. Based on NF-κB signaling pathway of Kuffer cells, the mechanism of Jiedu Huayu Granule in antagonizing liver failure was discussed[J]. China J Tradit Chin Med Pharm, 2021, 36( 4): 1878- 1883. 王挺帅, 张荣臻, 王明刚, 等. 基于Kuffer细胞NF-κB信号通路探讨解毒化瘀颗粒拮抗肝功能衰竭的作用机制[J]. 中华中医药杂志, 2021, 36( 4): 1878- 1883.
[9]	ZHANG K, MAO DW, WANG MG, et al. To explore the regulation of Jiedu Huayu granule on hepatocytepyroptosis in Acute liver failure mice based on AIM2 inflammasomesignaling pathway[J/OL]. Liaoning J Tradit Chin Med, 1- 18[ 2025-07-23]. https://link.cnki.net/urlid/21.1128.R.20250716.0845.002. https://link.cnki.net/urlid/21.1128.R.20250716.0845.002 张衎, 毛德文, 王明刚, 等. 基于AIM2炎症小体信号通路探讨解毒化瘀颗粒调控急性肝衰竭小鼠肝细胞焦亡的实验研究[J/OL]. 辽宁中医杂志, 1- 18[ 2025-07-23]. https://link.cnki.net/urlid/21.1128.R.20250716.0845.002. https://link.cnki.net/urlid/21.1128.R.20250716.0845.002
[10]	MAO DW, QIU H, YU J, et al. Protective effect of Jiedu Huayu Ⅱ recipe on experimental fulminant liver failure in rats[J]. Tradit Chin Med Res, 2006, 19( 12): 8- 10. DOI: 10.3969/j.issn.1001-6910.2006.12.005. 毛德文, 邱华, 余晶, 等. 解毒化瘀Ⅱ方对实验性暴发性肝衰竭大鼠的保护作用[J]. 中医研究, 2006, 19( 12): 8- 10. DOI: 10.3969/j.issn.1001-6910.2006.12.005.
[11]	WANG TS, MAO DW, ZHANG RZ, et al. Relationship between expression of Toll-like receptors and inflammatory cytokine on acute liver failure rats with Jiedu Huayu granule[J]. Chin Arch Tradit Chin Med, 2018, 36( 9): 2167- 2171. DOI: 10.13193/j.issn.1673-7717.2018.09.029. 王挺帅, 毛德文, 张荣臻, 等. 解毒化瘀颗粒对急性肝衰竭大鼠TOLL样受体表达与炎性细胞因子关系的研究[J]. 中华中医药学刊, 2018, 36( 9): 2167- 2171. DOI: 10.13193/j.issn.1673-7717.2018.09.029.
[12]	ZHANG RY, WU FL, CHEN YQ, et al. Exploring the mechanism of Jiedu Huayu granule on inflammatory response in acute liver failure based on the IL-6/JAK2/STAT3 axis[J/OL]. Liaoning J Tradit Chin Med, 1- 16[ 2025-07-23]. https://link.cnki.net/urlid/21.1128.R.20250819.1508.002. https://link.cnki.net/urlid/21.1128.R.20250819.1508.002 张日云, 吴凤兰, 陈月桥, 等. 基于IL-6/JAK2/STAT3轴探讨解毒化瘀颗粒对急性肝衰竭炎症反应的作用机制[J/OL]. 辽宁中医杂志, 1- 16[ 2025-07-23]. https://link.cnki.net/urlid/21.1128.R.20250819.1508.002. https://link.cnki.net/urlid/21.1128.R.20250819.1508.002
[13]	YANG B, CHEN S, XIA XQ, et al. Mas signaling potentiates neutrophil extracellular traps formation induced by endothelial cells derived S1P in mice with acute liver failure[J]. Adv Sci, 2025, 12( 20): 2411428. DOI: 10.1002/advs.202411428.
[14]	STRAVITZ RT, LEE WM. Acute liver failure[J]. Lancet, 2019, 394( 10201): 869- 881. DOI: 10.1016/s0140-6736(19)31894-x.
[15]	FERNÁNDEZ J, BASSEGODA O, TOAPANTA D, et al. Acute liver failure: A practical update[J]. JHEP Rep, 2024, 6( 9): 101131. DOI: 10.1016/j.jhepr.2024.101131.
[16]	ALVAREZ-SOLA G, URIARTE I, LATASA MU, et al. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications[J]. Biochim Biophys Acta BBA Mol Basis Dis, 2018, 1864( 4): 1326- 1334. DOI: 10.1016/j.bbadis.2017.06.025.
[17]	CZARNECKA AM, MILEWSKI K, ALBRECHT J, et al. The status of bile acids and farnesoid X receptor in brain and liver of rats with thioacetamide-induced acute liver failure[J]. Int J Mol Sci, 2020, 21( 20): 7750. DOI: 10.3390/ijms21207750.
[18]	XU WF, WANG Y, CUI S, et al. Methylcobalamin protects against liver failure via engaging gasdermin E[J]. Nat Commun, 2025, 16: 1233. DOI: 10.1038/s41467-024-54826-6.
[19]	CHEUNG A, FLAMM S. Hepatobiliary complications in critically ill patients[J]. Clin Liver Dis, 2019, 23( 2): 221- 232. DOI: 10.1016/j.cld.2018.12.005.
[20]	WANG MQ, ZHANG KH, LIU FL, et al. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress[J]. Phytomedicine, 2024, 122: 155124. DOI: 10.1016/j.phymed.2023.155124.
[21]	JIA SQ, DOU XG. Farnesol X receptor and its agonist and liver diseases[J]. Chin Hepatol, 2021, 26( 11): 1293- 1297. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.028. 贾锶琦, 窦晓光. 法尼醇X受体及其激动剂与肝脏疾病[J]. 肝脏, 2021, 26( 11): 1293- 1297. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.028.
[22]	MOHAMMED TA, ZALZALA MH. Hepatoprotective effects of cilnidipine in cholestatic liver disease: Role of FXR and NRF2 signalling[J]. J Exp Pharmacol, 2025, 17: 93- 105. DOI: 10.2147/JEP.S504511.
[23]	XIE XM, ZHANG BY, FENG S, et al. Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice[J]. Microbiol Spectr, 2025, 13( 4): e03150-24. DOI: 10.1128/spectrum.03150-24.
[24]	SONG LT, HOU YS, XU D, et al. Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress[J]. Cell Metab, 2025, 37( 1): 104- 120.e9. DOI: 10.1016/j.cmet.2024.09.008.
[25]	LI Y, LIU TY, ZHANG WJ. Research progress on the role of hepatoenteric farnesoid X receptor in metabolic diseases[J]. Tianjin Pharm, 2023, 35( 1): 71- 78. DOI: 10.3969/j.issn.1006-5687.2023.01.015. 李云, 刘天宇, 张文军. 肝肠法尼酯X受体在代谢性疾病中的作用研究进展[J]. 天津药学, 2023, 35( 1): 71- 78. DOI: 10.3969/j.issn.1006-5687.2023.01.015.
[26]	LYU L, WANG J, ZHANG QY. Effect of Yinchensiling granules combined with rifaximin on gut microbiota and intestinal barrier function in mice with acute liver failure[J]. Chin J Immunol, 2025, 41( 8): 1833- 1839. DOI: 10.3969/j.issn.1000-484X.2025.08.007. 吕琳, 王京, 张琪瑶. 茵陈四苓颗粒联合利福昔明对急性肝衰竭小鼠肠道菌群及肠屏障功能的影响[J]. 中国免疫学杂志, 2025, 41( 8): 1833- 1839. DOI: 10.3969/j.issn.1000-484X.2025.08.007.
[27]	ZHU ZW, YANG Y, ZHAO JH, et al. Mechanism of Yinchenhao decoction in ameliorating cholestatic liver injury by inhibiting the TLR4/MyD88/NF-κB pathway via FXR[J/OL]. Chin J Exp Tradit Med Form, 1- 10[ 2025-07-23]. https://doi.org/10.13422/j.cnki.syfjx.20251194. DOI: 10.13422/j.cnki.syfjx.20251194 朱正望, 杨洋, 赵静涵, 等. 茵陈蒿汤通过FXR抑制TLR4/MyD88/NF-κB通路改善胆汁淤积性肝损伤的机制[J/OL]. 中国实验方剂学杂志, 1- 10[ 2025-07-23]. https://doi.org/10.13422/j.cnki.syfjx.20251194. DOI: 10.13422/j.cnki.syfjx.20251194
[28]	DENG XY, WU HF, LI YB, et al. Mechanism of paeonilforin on ameliorating α-naphthylisothiocyanate-induced cholestasis based on bile acid metabolomics[J]. Chin Tradit Herb Drugs, 2024, 55( 1): 148- 158. DOI: 10.7501/j.issn.0253-2670.2024.01.016. 邓昕雨, 吴和霏, 李煜兵, 等. 基于胆汁酸代谢组学探讨芍药苷改善α-萘异硫氰酸酯诱导胆汁淤积的作用机制[J]. 中草药, 2024, 55( 1): 148- 158. DOI: 10.7501/j.issn.0253-2670.2024.01.016.
[29]	WANG WC, MA YP, WANG M, et al. Investigating the therapeutic effect of emodin on cholestatic liver injury in mice based on the CYP 7 A 1/FXR/SHP pathway[J/OL]. Chin J Clin Pharmacol Ther, 1- 10[ 2025-07-23]. https://link.cnki.net/urlid/34.1206.R.20250528.0830.002. https://link.cnki.net/urlid/34.1206.R.20250528.0830.002 王玮辰, 马雅萍, 王萌, 等. 基于CYP 7 A 1/FXR/SHP途径探究大黄素对胆汁淤积性肝损伤小鼠的治疗作用[J/OL]. 中国临床药理学与治疗学, 1- 10[ 2025-07-23]. https://link.cnki.net/urlid/34.1206.R.20250528.0830.002. https://link.cnki.net/urlid/34.1206.R.20250528.0830.002
[30]	ZHONG YH, LI YY, LIN Z, et al. Study on hepatoprotective effect of hedyotidis diffusae herba on ANIT-induced cholestasis in rats[J]. Tradit Chin Drug Res Clin Pharmacol, 2021, 32( 7): 952- 958. DOI: 10.19378/j.issn.1003-9783.2021.07.008. 钟艳花, 李颖仪, 林重, 等. 白花蛇舌草对ANIT诱导的胆汁淤积大鼠保肝作用研究[J]. 中药新药与临床药理, 2021, 32( 7): 952- 958. DOI: 10.19378/j.issn.1003-9783.2021.07.008.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (61) PDF downloads(29)

Regulatory effect of Jiedu Huayu granules on liver injury in mice with acute liver failure and its mechanism

DOI: 10.12449/JCH260117

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Regulatory effect of Jiedu Huayu granules on liver injury in mice with acute liver failure and its mechanism

DOI: 10.12449/JCH260117

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content